The FDA needs a few more weeks to decide the fate of Moderna's RSV vaccine, the company announced. A decision is now slated ...
Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for respiratory syncytial virus due to “administrative constraints,” extending a ...
Just days before its initial deadline, U.S. regulators say they need more time to decide whether or not to approve Moderna's ...
Key Takeaways Moderna said the Food and Drug Administration (FDA) has delayed its approval decision for the respiratory ...
The FDA has not informed Moderna of any issues related to the vaccine's safety, efficacy or quality that would prevent its ...
US regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to “administrative ...
(Reuters) – The U.S. Food and Drug Administration has pushed back its decision on Moderna’s respiratory syncytial virus (RSV) vaccine by more than two weeks to the end of this month due to some ...
Moderna announced that the FDA had delayed approval of its RSV vaccine to the end of May due to "administrative constraints" at the agency. The FDA was originally expected to make a decision on ...
"We don't expect major delays from here onwards and FDA should be able to approve this by end of May," Jefferies analyst Michael Yee said. Moderna has been banking on its experimental shots to make up ...